Literature DB >> 20636791

Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas.

Panagiotis Bakarakos1, Irene Theohari, Alexandros Nomikos, Eleni Mylona, Christos Papadimitriou, Athanasios-Meletios Dimopoulos, Lydia Nakopoulou.   

Abstract

AIMS: Loss of phosphatase and tensin homologue (PTEN) leads to activation of several kinases, including mammalian target of rapamycin (mTOR), which promotes cell cycle progression. The aim was to study the expression of PTEN and phosphorylated (p)-mTOR in familial and sporadic invasive breast carcinomas and their relation to clinicopathological features, molecular indices (Wnt1) and patients' survival. METHODS AND
RESULTS: PTEN and p-mTOR were detected immunohistochemically in 215 sections of invasive breast carcinomas (112 with a familial history of breast cancer). Image analysis was used and univariate and multivariate analyses employed for statistical evaluation of results. PTEN was detected in the nucleus (73.5%) and p-mTOR in the cytoplasm (44.2%) of cancer cells. Loss of PTEN protein was more frequently detected in women with a familial history of breast cancer (72%) (P < 0.0001), while its expression was negatively correlated with Wnt1, in total (P = 0.049). p-mTOR showed a positive association with lymph node status (P = 0.010) and was found to have a negative impact on patients' overall survival (P = 0.016).
CONCLUSIONS: Loss of PTEN protein expression appears to occur more frequently in women with a family history of breast cancer, whereas activation of mTOR protein seems to be related to a more aggressive phenotype.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20636791     DOI: 10.1111/j.1365-2559.2010.03570.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  16 in total

1.  A pathogenic role for germline PTEN variants which accumulate into the nucleus.

Authors:  Janire Mingo; Isabel Rodríguez-Escudero; Sandra Luna; Teresa Fernández-Acero; Laura Amo; Amy R Jonasson; Roberto T Zori; José I López; María Molina; Víctor J Cid; Rafael Pulido
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

2.  Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma.

Authors:  Tomofumi Naruse; Souichi Yanamoto; Shin-ichi Yamada; Satoshi Rokutanda; Akiko Kawakita; Goro Kawasaki; Masahiro Umeda
Journal:  Pathol Oncol Res       Date:  2015-02-15       Impact factor: 3.201

3.  Oxadiazol-based mTOR inhibitors with potent antiproliferative activities: synthetic and computational modeling.

Authors:  Mohammad A Khanfar
Journal:  Mol Divers       Date:  2022-01-05       Impact factor: 2.943

4.  Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas.

Authors:  Shir-Hwa Ueng; Shin-Cheh Chen; Yu-Sun Chang; Swei Hsueh; Yung-Chang Lin; Hui-Ping Chien; Yun-Feng Lo; Shih-Che Shen; Chuen Hsueh
Journal:  Int J Clin Exp Pathol       Date:  2012-10-01

5.  Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma.

Authors:  Min Li; Huawen Sun; Lujun Song; Xiaodong Gao; Wenju Chang; Xinyu Qin
Journal:  Oncol Lett       Date:  2012-09-21       Impact factor: 2.967

6.  Olive Oil-derived Oleocanthal as Potent Inhibitor of Mammalian Target of Rapamycin: Biological Evaluation and Molecular Modeling Studies.

Authors:  Mohammad A Khanfar; Sanaa K Bardaweel; Mohamed R Akl; Khalid A El Sayed
Journal:  Phytother Res       Date:  2015-08-07       Impact factor: 5.878

7.  Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population.

Authors:  Martha L Slattery; Esther M John; Gabriela Torres-Mejia; Abbie Lundgreen; Jennifer S Herrick; Kathy B Baumgartner; Lisa M Hines; Mariana C Stern; Roger K Wolff
Journal:  Carcinogenesis       Date:  2012-05-04       Impact factor: 4.944

8.  Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.

Authors:  Kangwu Chen; Jianqiang Mo; Ming Zhou; Genlin Wang; Guizhong Wu; Hao Chen; Kai Zhang; Huilin Yang
Journal:  Med Oncol       Date:  2014-02-18       Impact factor: 3.064

9.  Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance.

Authors:  Shu-Chen Liu; Ngan-Ming Tsang; Wen-Che Chiang; Kai-Ping Chang; Chuen Hsueh; Ying Liang; Jyh-Lyh Juang; Kai-Ping N Chow; Yu-Sun Chang
Journal:  J Clin Invest       Date:  2013-11-25       Impact factor: 14.808

10.  Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.

Authors:  Josefine Bostner; Elin Karlsson; Muneeswaran J Pandiyan; Hanna Westman; Lambert Skoog; Tommy Fornander; Bo Nordenskjöld; Olle Stål
Journal:  Breast Cancer Res Treat       Date:  2012-12-15       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.